MARKET

LLY

LLY

Lilly
NYSE

Real-time Quotes | Nasdaq Last Sale

221.19
+2.64
+1.21%
Opening 10:28 06/21 EDT
OPEN
218.81
PREV CLOSE
218.55
HIGH
221.72
LOW
218.08
VOLUME
589.17K
TURNOVER
--
52 WEEK HIGH
235.85
52 WEEK LOW
129.21
MARKET CAP
212.13B
P/E (TTM)
33.13
1D
5D
1M
3M
1Y
5Y
BRIEF-Eli Lilly Canada - On June 15, Health Canada Issued Notice Of Compliance With Conditions (Noc/C) For Retevmo
reuters.com · 2h ago
Eli Lilly Canada Reports Health Canada Issued Notice Of Compliance With Conditions For Retevmo
-Reuters
Reuters · 2h ago
Notice of Compliance with Conditions granted for Retevmo™ (selpercatinib), the first therapy in Canada specifically for patients with advanced RET-driven lung and thyroid cancers
COMTEX_388609751/2669/2021-06-21T08:01:57
CNW Group · 2h ago
Eli Lilly, Boehringer Ingelheim's Jardiance Gets Approval in Europe for Treatment of Chronic Heart Failure
MT Newswires · 7h ago
Biohaven gains on takeover speculation following board appointment
tommaso79/iStock via Getty Images Biohaven Pharmaceutical (BHVN) gained 1.8% after adding a portfolio manager from Suvretta Capital onto its board, an appointment that appears to be leading to takeover speculation. Biohaven hired
Seekingalpha · 2d ago
Pharmaceutical CEO on Biden’s support for COVID-19 vaccine waiver: ‘It just seems self-defeating’
In May, the Biden administration backed the idea of waiving intellectual property protections for COVID-19 vaccines. In a new interview, pharmaceutical giant Eli Lilly CEO David Ricks weighed in says “this is a counterproductive move.”
Yahoo Finance · 3d ago
Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal
AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.
Zacks · 3d ago
Global Acute Otitis Media Treatment Market Size, Share Remuneration to Surge At 5% CAGR Through 2025 - Industry Report
Selbyville, Delaware. The report Acute Otitis Media Treatment Market Size and Analysis maintains enhanced dynamics and is overshadowed by a top player across the globe. The research report provides Acute Otitis Media Treatment Market Growth and information...
Market Insight Reports · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LLY. Analyze the recent business situations of Lilly through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 22 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LLY stock price target is 216.36 with a high estimate of 270.00 and a low estimate of 175.00.
EPS
Institutional Holdings
Institutions: 2.38K
Institutional Holdings: 834.49M
% Owned: 87.01%
Shares Outstanding: 959.03M
TypeInstitutionsShares
Increased
652
49.28M
New
171
2.31M
Decreased
756
37.35M
Sold Out
94
6.48M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.66%
Pharmaceuticals & Medical Research
+0.56%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Ricks
Chief Financial Officer/Senior Vice President
Anat Ashkenazi
Senior Vice President/Chief Information Officer
Aarti Shah
Senior Vice President/Chief Scientific Officer
Daniel Skovronsky
Senior Vice President/Chief Compliance Officer
Melissa Barnes
Senior Vice President/General Counsel/Secretary
Anat Hakim
Senior Vice President/Director of Human Resources
Stephen Fry
Senior Vice President
Patrik Jonsson
Senior Vice President
Michael Mason
Senior Vice President
Johna Norton
Senior Vice President
Myles O'Neill
Senior Vice President
Leigh Pusey
Senior Vice President
Anne White
Senior Vice President
Ilya Yuffa
Senior Vice President
Alfonso Zulueta
Independent Director
Ralph Alvarez
Lead Director/Independent Director
Juan Luciano
Independent Director
Raul Alvarez
Independent Director
Katherine Baicker
Independent Director
Carolyn Bertozzi
Independent Director
Michael Eskew
Independent Director
J. Erik Fyrwald
Independent Director
Jamere Jackson
Independent Director
Kimberly Johnson
Independent Director
William Kaelin
Independent Director
Marschall Runge
Independent Director
Gabrielle Sulzberger
Independent Director
Jackson Tai
Independent Director
Karen Walker
Declaration Date
Dividend Per Share
Ex-Div Date
05/03/2021
Dividend USD 0.85
05/13/2021
12/14/2020
Dividend USD 0.85
02/11/2021
10/19/2020
Dividend USD 0.74
11/12/2020
07/15/2020
Dividend USD 0.74
08/13/2020
05/04/2020
Dividend USD 0.74
05/14/2020
12/16/2019
Dividend USD 0.74
02/13/2020
10/21/2019
Dividend USD 0.645
11/14/2019
06/19/2019
Dividend USD 0.645
08/14/2019
05/06/2019
Dividend USD 0.645
05/16/2019
12/19/2018
Dividend USD 0.645
02/14/2019
10/15/2018
Dividend USD 0.563
11/14/2018
06/18/2018
Dividend USD 0.563
08/14/2018
05/07/2018
Dividend USD 0.563
05/16/2018
12/11/2017
Dividend USD 0.563
02/14/2018
10/16/2017
Dividend USD 0.52
11/14/2017
06/19/2017
Dividend USD 0.52
08/11/2017
05/01/2017
Dividend USD 0.52
05/11/2017
12/13/2016
Dividend USD 0.52
02/13/2017
10/18/2016
Dividend USD 0.51
11/10/2016
06/20/2016
Dividend USD 0.51
08/11/2016
  • All
  • Financials
  • Insiders
More
About LLY
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Webull offers kinds of Eli Lilly And Co stock information, including NYSE:LLY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LLY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LLY stock methods without spending real money on the virtual paper trading platform.